Phase I Study of GS-3583, a FLT3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors

CONCLUSIONS: GS-3583 was relatively well tolerated and induced dose-dependent expansion of cDCs in the periphery of patients with advanced solid tumors. However, development of a second primary malignancy provides a cautionary tale for the FLT3 agonist mechanism.PMID:38295150 | DOI:10.1158/1078-0432.CCR-23-2808

Source: Clinical Cancer Research - January 31, 2024 Category: Cancer & Oncology Authors: Anthony W Tolcher Joshua D Brody Nishanthan Rajakumaraswamy Michelle Kuhne Torsten Trowe Anees M Dauki Shantheri Kochikar Pai Ling Han Kai-Wen Lin Michael Petrarca Shivaani Kummar Source Type: research